BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 23460251)

  • 21. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
    Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
    Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voriconazole concentrations and outcome of invasive fungal infections.
    Miyakis S; van Hal SJ; Ray J; Marriott D
    Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preemptive treatment with voriconazole in lung transplant recipients.
    Neoh CF; Snell GI; Levvey B; Kotsimbos T; Morrissey CO; Slavin MA; Stewart K; Kong DC
    Transpl Infect Dis; 2013 Aug; 15(4):344-53. PubMed ID: 23527908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
    Lewis G; Hall P; Eisa N; Deremer D; Dobbins R; El-Geneidy M; Jillella A; Ustun C
    Acta Haematol; 2010; 124(4):206-13. PubMed ID: 21071929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
    Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
    BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
    Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
    Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
    Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
    Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
    Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
    Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
    Tey A; Shaw B; Cardamone L; Shepherd S; Paul E; Rogers B; Shortt J
    Eur J Haematol; 2021 Aug; 107(2):181-189. PubMed ID: 33829584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: a real-world, retrospective comparative single-centre study.
    Gerber B; Köppel J; Paul M; Nguyen-Kim TD; Frauenfelder T; Nair G; Schanz U; Manz MG
    Swiss Med Wkly; 2014; 144():w13985. PubMed ID: 25055166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
    Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
    Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
    Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
    Bose P; McCue D; Wurster S; Wiederhold NP; Konopleva M; Kadia TM; Borthakur G; Ravandi F; Masarova L; Takahashi K; Estrov Z; Yilmaz M; Daver N; Pemmaraju N; Naqvi K; Rausch CR; Marx KR; Qiao W; Huang X; Bivins CA; Pierce SA; Kantarjian HM; Kontoyiannis DP
    Clin Infect Dis; 2021 May; 72(10):1755-1763. PubMed ID: 32236406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
    Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
    Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis of invasive fungal infections using real-time PCR assay in paediatric acute leukaemia induction.
    Mandhaniya S; Iqbal S; Sharawat SK; Xess I; Bakhshi S
    Mycoses; 2012 Jul; 55(4):372-9. PubMed ID: 22420668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit.
    Yunus S; Pieper S; Kolve H; Goletz G; Jürgens H; Groll AH
    J Antimicrob Chemother; 2014 Mar; 69(3):815-20. PubMed ID: 24198097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; O'Brien S; Kontoyiannis DP; Giles F; Zhou X; Lim J; Bekele BN; Faderl S; Cortes J; Pierce S; Leitz GJ; Raad I; Estey E
    Cancer; 2004 Feb; 100(3):568-73. PubMed ID: 14745874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.